Cell Banking Outsourcing Market Size, Share, Opportunities, And Trends By Type (Master Cell Banking, Working Cell Banking, Viral Cell Banking), By Cell (Stem Cell, Non-Stem Cell), By End-Users (Bank Storage, Bank Characteristics & Testing, Bank Preparation), And By Geography - Forecasts From 2023 To 2028

  • Published : Dec 2023
  • Report Code : KSI061615812
  • Pages : 148

The cell banking outsourcing market is estimated to grow at a CAGR of 12.65% during the forecast period.

Cell banking outsourcing consists of a diverse array of services that encompass essential activities like the storage, collection, characterization, and testing of cells, cell lines, and tissues. It offers cell lines, cells, and tissues for research and development, as well as biopharmaceutical production. Cell banks aim to provide maximum efficacy and minimize adverse events. The cell banking outsourcing market is primarily driven by the rapid growth of biotech industries and the increasing adoption of cell-based therapies.

Emerging biotech industries drive the cell banking outsourcing market expansion.

Cell banking processes and preserves cells, typically stem cells, in controlled environments for future use in various medical treatments and research applications. Favorable Investments in cell banking can significantly boost the growth of the cell banking outsourcing market. For instance, in September 2021, LifeCell International, a leading provider of stem cell banking and reproductive testing services, secured Rs 225 crore in equity funding from OrbiMed Asia Partners. The raised capital would be instrumental in supporting the company's growth strategy for its various divisions, as well as expanding its range of tests in the genomic sector.

Increasing cell-based therapies drives the cell banking outsourcing market expansion.

Cell banking outsourcing is utilized in cell-based therapies to meet the growing demand for well-characterized and reliable cell lines, which are crucial for the development of advanced regenerative and personalized medicines. The expanding adoption of cell-based therapies stems from their potential to address unmet medical needs, provide personalized treatment options, and offer promising solutions for various diseases and conditions, driving significant growth in the cell banking outsourcing market. According to the American Society of Gene Cell Therapy, In the year 2022, the pipeline of gene, cell, and RNA therapies witnessed a notable growth of 7%, encompassing preclinical to pre-registration stages.

Regulatory compliance drive cell banking outsourcing market growth.

The cell banking industry is governed by stringent regulatory requirements aimed at guaranteeing the safety, efficacy, and traceability of biological materials utilized in pharmaceutical production. As a result, reputable cell banking outsourcing providers place great emphasis on adhering to rigorous quality and regulatory standards. By maintaining strict compliance and implementing robust processes, these providers instill confidence in pharmaceutical companies regarding the reliability and integrity of their cell banking services, thus fostering a trustworthy partnership that is essential for advancing research, development, and manufacturing activities in the pharmaceutical sector.

Asia-Pacific is expected to be the market leader

Asia Pacific will hold a significant share of the cell banking outsourcing market due to the improved government investments and initiatives aimed at fostering biotech industries and advancing cell-based therapies in the region. Hence, with substantial financial support and supportive policies, Asian-Pacific countries have cultivated a conducive environment for biotech companies to flourish, thereby increasing the demand for specialized cell banking services. In Feb 2023,  to boost domestic production of high-value formulations, critical APIs (Active Pharmaceutical Ingredients), and high-end medical devices, the government of India released Rs. 166 Crores in incentives under the PLI scheme for Pharmaceuticals encompassing various products, including cell-based or gene-therapy drugs.

Confidentiality concerns restrain the cell banking outsourcing market growth.

The reluctance of biotech companies to engage in cell banking outsourcing stems from their concerns about sharing sensitive information and proprietary knowledge with external partners, primarily due to the perceived risk of data breaches or breaches of confidentiality. This hesitancy can act as a significant restraint for the cell banking outsourcing market growth, as companies prioritize safeguarding their intellectual property and maintaining control over critical biological assets. Addressing these confidentiality and security concerns through robust data protection measures and building trusted partnerships with outsourcing providers is crucial to fostering greater confidence in the outsourcing process and unlocking the full potential of the cell banking outsourcing market.

Key Developments

  • June 2023: Extracellular, a pioneering company in the cultivated meat industry, announced the launch of license-free cell banks dedicated to supporting cultivated meat research. These cell banks are equipped with primary cells specifically relevant to cultivated meat studies and have been developed through funding from InnovateUK, in collaboration with Multus. By providing access to these specialized cell resources without licensing fees, Extracellular aims to accelerate research and innovation in the field of cultivated meat, promoting sustainable and ethical alternatives to traditional meat production methods.
  • April 2023: AnaBios, a San Diego-based preclinical contract research organization (CRO), completed the acquisition of Cell Systems, a group specializing in human primary cells and cell culture media. This strategic deal enables AnaBios to enhance its portfolio with a broader range of human tissue and cells, further strengthening its capabilities to provide comprehensive preclinical research services.
  • January 2023: The Technology Partnership company introduced a spin-out entity called Cellular Origins, aimed at revolutionizing the production of cell and gene therapies with scalable and cost-effective manufacturing solutions. Cellular Origins offers a proprietary technology that tackles the challenges of manufacturing advanced therapies in later stages of development. Their adaptable automated sterile fluidic end-to-end interconnection system can seamlessly integrate into existing and future bioprocess equipment, enabling comprehensive automation across the manufacturing workflow.
  • June 2021: Generate Life Sciences (Generate) has recently made an acquisition of the Cell Care international cord blood banking group (Cell Care), encompassing Cell Care in Australia, along with Inspection Lifebank and Cells for Life in Canada. With this merger, Cell Care becomes a part of Generate's Cord Blood Registry, forming a global network of newborn stem cell banks dedicated to advancing collective research in regenerative medicine.

Company Products

  • cGMP-compliant cell banking services: GBI offers comprehensive cGMP-compliant cell banking services, encompassing research, master, and working cell banks (RCB, MCB, and WCB). These banks are meticulously prepared using a controlled-rate freezing system and securely stored in cryogenic vapor-phase liquid nitrogen storage chambers. Each cell bank undergoes rigorous testing, adhering to the latest industry Points to Consider, ensuring the highest quality and regulatory compliance for the storage and preservation of valuable cell resources.

Cell Banking Outsourcing Market Scope:


Report Metric Details
Growth Rate CAGR of 12.65% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered
  • Type
  • Cell
  • Phase
  • Geography
Companies Covered
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope Free report customization with purchase



  • By Type
    • Master Cell Banking
    • Working Cell Banking
    • Viral Cell Banking
  • By Cell
    • Stem Cell
    • Non-Stem Cell
  • By Phase
    • Bank Storage
    • Bank Characteristics & Testing
    • Bank Preparation
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Master Cell Banking

5.3. Working Cell Banking

5.4. Viral Cell Banking


6.1. Introduction

6.2. Stem Cell

6.3. Non-stem Cell


7.1. Introduction

7.2. Bank Storage

7.3. Bank Characteristics & Testing

7.4. Bank Preparation


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. Bio Outsource (Sartorious)

10.2. BSL Bioservice

10.3. Cryo-Cell International, Inc

10.4. Charles River Laboratories

10.5. LifeCell

10.6. GBI

10.7. Lonza

10.8. SGS Société Générale de Surveillance SA

10.9. Perfectus Biomed Limited

Bio Outsource (Sartorious)

BSL Bioservice

Cryo-Cell International, Inc

Charles River Laboratories




SGS Société Générale de Surveillance SA

Perfectus Biomed Limited